Marx J J, Stiekema J
Eur J Clin Pharmacol. 1982 Oct;23(4):335-8. doi: 10.1007/BF00613616.
The absorption of a pharmacological dose of iron was assessed by determination of mucosal uptake, mucosal transfer and retention of 33 mg (Fe(II) as ferrous sulphate and ferrous ascorbate. 20 subjects were studed in a cross-over trial, 11 with normal iron stores and 9 with iron deficiency according to the serum ferritin concentrations. The activity of 59Fe and 51Cr (administered as a non-absorbable indicator) was measured by whole-body counting. There was no difference in absorption between the two iron compounds in normal subjects. Absorption of ferrous ascorbate averaged 52% higher than ferrous sulphate in subjects with iron deficiency. The difference was the result of higher mucosal uptake, probably because oxidation of Fe(II) in the alkaline milieu of the intestine, which leads to formation of non-absorbable Fe(III) complexes, was prevented. The mucosal transfer fraction of both compounds was identical.
通过测定33毫克铁（以硫酸亚铁和抗坏血酸亚铁形式存在的Fe(II)）的黏膜摄取、黏膜转运和潴留情况，评估药理剂量铁的吸收。在一项交叉试验中研究了20名受试者，根据血清铁蛋白浓度，其中11人铁储备正常，9人缺铁。通过全身计数测量59Fe和51Cr（作为不可吸收指示剂给药）的活性。正常受试者中两种铁化合物的吸收没有差异。缺铁受试者中抗坏血酸亚铁的吸收平均比硫酸亚铁高52%。这种差异是由于黏膜摄取较高，可能是因为肠道碱性环境中Fe(II)的氧化导致形成不可吸收的Fe(III)络合物的过程被阻止。两种化合物的黏膜转运转运分数相同。
